there is a Euroz report from 5th of April after bot completed the mid-cycle review.
from that analyst report:
Acknowledging these businesses vary in different ways (business model, disease areas, existing licensing agreements, ex-US approvals, and product portfolios), indicatively the market has paid:
7x to 23x (14x average) 2-year forward Revenues;
and 15x to 90x (45x average) 2-year forward EBITDA
This highlight the potential valuation upside if BOT can deliver an even modestly successful commercial launch of Sofpironium Bromide.
figures below are in USD
BOT - Anything but charting, page-7488
-
- There are more pages in this discussion • 3,740 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.005(1.43%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 36.0¢ | 34.5¢ | $1.255M | 3.601M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 206282 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 316320 | 5 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |